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Abstract
Melanoma is the deadliest of all skin cancers due to its high metastatic potential. In recent
years, advances in targeted therapy and immunotherapy have contributed to a remarkable
progress in the treatment of metastatic disease. However, intrinsic or acquired resistance
to such therapies remains a major obstacle in melanoma treatment. Melanoma disease
progression, beginning from tumor initiation and growth to acquisition of invasive pheno-
types and metastatic spread and acquisition of treatment resistance, has been associated
with cellular dedifferentiation and the hijacking of gene regulatory networks reminiscent
of the neural crest (NC)—the developmental structure which gives rise to melanocytes and
hence melanoma. This review summarizes the experimental evidence for the involvement
of NC stem cell (NCSC)-like cell states during melanoma progression and addresses novel
approaches to combat the emergence of stemness characteristics that have shown to be
linked with aggressive disease outcome and drug resistance.
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1 | INTRODUCTION
The neural crest (NC) is a transient and multipotent stem cell population
arising at the dorsal neural tube at early stages of vertebrate develop-
ment.1-3 Neural crest stem cells (NCSCs) disseminate into the embryo
to differentiate into an array of cell lineages with remarkably different
functions.4 Among the adult NC derivatives are cartilage and bone
structures in the head, the outflow tract of the heart, enteric nervous
system cells in the gut, neuronal and non-neuronal cells of the periph-
eral nervous system, melanocytes and others.5,6
While most of the NC progeny have acquired a fully differen-
tiated fate in the adult, cells with NCSC-like characteristics have
been isolated from several adult mouse tissues7 as well as human
skin8-12 and dental pulp.13 Even though the isolated cells
possessed multipotent capacities in vitro and could give rise
to different NC lineages, the question remains whether NCSC-
like cells derived from adult tissues really represent a maintained
embryonic stem cell niche or whether these cells reacquire
stem cell features due to isolation procedures and cultivation
in vitro.
The reemergence of NCSC-like cell states in vivo has been observed
and studied in the context of pathological and physiological conditions
such as carcinogenic transformations of NC-derived adult tissues or
wound healing, respectively. Murine tissue injury models revealed that
NC-derived Schwann cells (peripheral glia) dedifferentiate after injury and
reacquire a progenitor-like cell state by downregulating genes crucial for
the myelination machinery and upregulating NCSC-associated factors
such as the neurotrophin receptor CD271 (also p75NTR, NGFR).14,18
Injury-activated glial cells were further shown to crucially assist regenera-
tion of full-thickness skin wounds or amputated digit tips.17,18
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Furthermore, previous reports revealed that Schwann cell precursors
(SCPs) during embryonic development harbor NC cell features and are
able to generate a variety of neural and non-neural cell types.15,16 Like-
wise, carcinogenic lesions of adult NC-derived tissues such as melanoma
or neuroblastoma can both present with cells expressing NCSC-associ-
ated factors that are not normally expressed in the healthy adult tis-
sue.19-21 This review focuses on melanoma, wherein the aberrant
regulation or expression of developmental NCSC genes or pathways is
associated with different aspects of malignancy (Figure 1), such as tumor
initiation and sustained tumor growth,22-25 promotion of metastatic
spread,26 as well as resistance to therapies27-30 and immune evasion.31,32
2 | DEVELOPMENTAL NCSC GENES
REGULATE MELANOMA GROWTH AND
HOMEOSTASIS
Cutaneous malignant melanoma, the most aggressive skin cancer,33
can present with astonishing heterogeneity, ranging from cells
expressing typical melanocyte differentiation genes to gene sets typi-
cal for other NC-derived cell lineages like neurons or glia, among
others.34-36 The origin of such heterogeneous tumors has been
heavily debated and research was carried out on the expression of
factors reminiscent of stem cells, which equips melanoma cells with
renewal capacities in vitro and tumor formation potential
in vivo.22,37,38 For instance, the neurotrophin receptor CD271, which
has been used for isolation of rat NCSCs with multipotent capacities
in vitro,14 was found reexpressed in a subset of melanoma cells that
were able to initiate tumor formation when grafted into immunocom-
promised mice, while CD271-negative cells lacked such potential22
F IGURE 1 Reacquisition of neural crest stem cell (NCSC)-like characteristics in melanoma and its implications. Embryonic NCSCs (dark green)
arise at the developing dorsal neural tube and migrate into the whole embryo to form different tissues such as craniofacial bone and cartilage,
enteric and peripheral nervous system cells (light grey) and, amongst many others, also cells of the melanocyte lineage, specifically melanocyte
stem cells (MeSCs), melanoblasts and melanocytes (brown). Due to malignant transformations, those cells can progress into melanoma. Different
studies have shown that some melanoma cells (light green) can hijack embryonic NCSC programs, bestowing them with different advantageous
characteristics. Melanoma cells with reacquired NCSC features have been associated with the ability to form novel tumors and sustain growth,
increased cell invasiveness and metastasis formation, as well as the ability to resist different melanoma therapies and evade immune surveillance
Significance statement
This review summarizes the experimental evidence for
reemergence of neural crest stem cell (NCSC)-like cells in
melanoma, which hijack embryonic programs to acquire
advantages regarding tumor initiation and growth, meta-
static spread, and eventually therapy resistance. Further-
more, the authors discuss preclinical efforts to specifically
target NCSC-like melanoma cells to combat drug resistance,
which is a major goal in the field and will hopefully soon
improve melanoma therapy for patients.
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(Table 1). Furthermore, the tumors grown from single grafted
CD271high cells presented with the heterogeneity of the parental
tumor from which they were isolated, and not exclusively of
CD271-positive cells as grafted to generate the tumor, supporting the
idea that CD271high cells represent stem cell-like cells.22 Of impor-
tance, CD271 is expressed in few adult cell types64,65 and exerts
divergent functions depending on the tissue context, for instance in
melanocytes versus transformed malignant melanoma.66,67 While sig-
nal transduction networks related to melanocytic differentiation (such
as skin development, metabolic hormone processes or cell adhesion)
have been found enriched in CD271-positive human melanocytes, the
same pathways were significantly downregulated in CD271-positive
human melanoma cells,66 supporting the association of CD271high cell
states with dedifferentiation and stemness potential in melanoma.
The idea that stem cell-like cells exist in melanoma was further
strengthened by the finding that apart from CD271, the expression of
other genes reminiscent of NCSCs was reported in melanoma and
found to be essential for tumor initiation and maintained tumor
growth. The transcription factor (TF) SRY-related HMG-box
10 (SOX10), for instance, which regulates the melanocytic and glial
murine lineages derived from the NC,39,40 was found highly expressed
in melanocytic nevi and malignant melanoma.24,68,69 Upon depletion
of SOX10 in a transgenic NRASQ61K-mutant, Ink4a-deficient murine
melanoma model, tumor growth was diminished, and silencing of
SOX10 in human melanoma cells drastically reduced the number of
cells expressing CD271 and completely abolished tumor growth
in vivo24 (Table 1). Similar to SOX10, the TF Ying Yang 1 (YY1) was
found to regulate both murine NC development and melanoma forma-
tion in NRASQ61K-mutant, Ink4a-deficient mice25 (Table 1). The impor-
tance of reemerging NCSC-like cell states during melanoma initiation
was highlighted in yet another study, where in BRAFV600E-mutant,
p53-deficient melanoma-prone zebrafish, cells capable of melanoma
initiation activated a gene regulatory program characterized by the
activation of zebrafish embryonic NC regulators such as crestin23
(Table 1). Similarly, a recent study identified a set of genes expressed
in embryonic melanoblasts, which are downregulated in fully differen-
tiated melanocytes but partially reexpressed in human metastasis
samples, providing further evidence for melanoma cells reacquiring
progenitor-like cell states.70 Consequently, some of those genes like
KDELR3 indeed proved to be essential for the formation of experi-
mental metastasis in a model of tail vain-injected murine B16 cells.70
Nevertheless, the role of some genes involved in NC develop-
ment remains unclear and heavily debated. SOX2, a member of the
SRY TF family like SOX10, for instance, was shown to regulate NCSCs
and SCPs together with MITF, while SOX2 downregulation led to pre-
cursor differentiation into melanocytes,71 suggesting that the
upregulation of SOX2 in melanoma might orchestrate stem cell-like
traits. However, while some studies report that SOX2 promotes tumor
initiation of human cells grafted into immunocompromised mice,72,73
others have shown that it is dispensable for melanomagenesis in
genetically engineered mouse models.74,75
While some factors reminiscent of NC development regulate cell
cycle regulatory networks to allow tumor initiation and maintenance
of adult melanoma, other cellular processes enabling melanoma tumor
formation such as transcriptional regulation44,45 or metabolism25 have
been shown to be regulated by NCSC-associated factors. It was
shown, for instance, that dihydroorotate dehydrogenase (DHODH),
an enzyme involved in nucleotide biosynthesis, is essential for tran-
scriptional elongation of genes crucial for both NC development and
melanoma formation and that hence, inhibition of DHODH
suppressed proper NC development as well as melanoma formation,
especially when combined with BRAF inhibition44 (Table 1). Mechanis-
tically, DHODH inhibition-induced nucleotide stress has recently been
linked to the RNA helicase DDX21, which senses nucleotide shortage
in NCSCs as well as melanoma cells, upon which it stops transcrip-
tional elongation45 (Table 1). In addition, DDX21 was found to regu-
late transcription in melanocyte stem cells (McSCs) in the hair follicle
bulge to prevent differentiation into melanocytes.76
There has been much debate recently about whether the cell at
the origin of melanoma indeed represents a stem cell-like cell. In fact,
the above-mentioned studies somewhat stand in contrast to reports
claiming that instead of cells with stem cell features, fully differenti-
ated melanocytes can give rise to melanoma. For instance, it was
shown that BRAFV600E-mutant, Pten-deficient fully differentiated and
melanin-producing melanocytes could give rise to melanoma.77 Of
importance, Köhler et al77 state in their study that after a first radial
growth phase initiated by fully differentiated melanocytes, a subset of
melanoma cells also underwent a transcriptional dedifferentiation pro-
cess potentially reminiscent of the reemergence of NCSC-like pro-
grams reported by others.
Yet another theory on the origin of melanoma argues that McSCs
residing in the bulge of the hair follicle, rather than differentiated
melanocytes, could stand at the origin of melanoma primary tumor
formation.78,79 Moreover, given that adult Schwann cells have the
capacity of dedifferentiation in vivo18 and that SCPs are able to gen-
erate melanocytes,80 it is conceivable that some melanoma might
derive from the peripheral glial lineage.
Several animal models have allowed melanoma induction with
specific cues followed by in-depth analysis and lineage tracing to
understand disease initiation and progression. However, such analyses
remain challenging in the context of human disease. While single-cell
studies of patient-derived melanoma allow unprecedented insights
into heterogeneous disease evolution, an alternative approach to
tackle melanoma origin as such, could be the artificial induction of
melanoma in melanocyte lineage cells derived from human embryonic
stem cells followed by lineage tracing and single-cell characterization.
Yet, the mystery of how human melanoma arises in vivo remains to be
unraveled.
3 | NCSC-LIKE CELLS CAN INDUCE
INVASION AND METASTATIC SPREAD OF
MELANOMA
Apart from inducing or maintaining melanoma tumor growth, the
reacquisition of NCSC-like characteristics has also been associated
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TABLE 1 Literature overview of NCSC-associated factors regulating parts of melanomagenesis
Melanoma implication Factor (function) Detailed function in melanoma References NCSC function References
Tumor Initiation/growth SOX10 (TF) Broadly expressed in human nevi
and melanomas. Depletion leads
to abolished tumor formation in a
NRASQ61K Ink4a-deficient mouse
model, associated with reduced
numbers of CD271+ cells.




YY1 (TF) Haploinsufficiency is enough to




pathways in neural crest and
melanoma.








Single CD271+ melanoma patient-
derived cells can form tumors
(with the heterogeneity of the
parental tumor) upon grafting into
immunocompromised mice, while
CD271- cells cannot. Inhibition of
CD271 in human melanoma cells
reduces their tumor initiation
potential.







Upregulated in human malignant
melanoma compared to
melanocytes. Depletion in a
NRASQ61K Ink4a-deficient mouse





















Crestin (unknown) Marks tumor-initiating cells in a
BRAFV600E p53-deficient zebrafish
melanoma model.
23 mRNA widely expressed
in zebrafish NCSCs
46
Phenotype switch/invasion MSX1 (TF) Induces phenotypic switching (E-
cadherinhigh, nonmigratory toward
ZEB1high, invasive) in melanoma.
Depletion reduces liver metastasis
after tail vain injection of human
melanoma cells into
immunocompromised mice.
47 NC induction in xenopus 48
Twist1/Zeb1 (TF) NRAS/BRAF activation in
melanocytes leads to upregulation




49 Twist1: NC specifier;
delamination of cranial










FOXD3 and PAX3 drive CXCR4
expression in melanoma, which
was shown to promote melanoma
metastasis formation.







metastasis in patients. Transient
35,26
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with later stages of melanoma progression, such as invasiveness and
metastatic spread.22,26,35 To become invasive and disseminate from
the primary tumor, cancer cells are thought to undergo an epithelial to
mesenchymal transition (EMT), rendering them with decreased cell-
to-cell contacts, increased motility, and an increased potential to
remodel extracellular matrix components.81,82
Although, by definition, classical EMT is a process associated
with epithelial cancers, which is not the case for melanoma, mela-
noma cells can undergo an EMT-like process called “phenotype
switching,” where cells transform from a high proliferative/low
invasive to a low proliferative/high invasive phenotype.83,84 Even
though it has been reported that melanoma invasion and metasta-
sis can progress independently of the ‘classical’ phenotype
switching model,85 EMT-like phenotype switching is thought to be
a crucial driver of melanoma invasiveness and metastasis
formation.86
Migratory NCSCs delaminating from the neural tube to migrate
out into the embryo are a paradigm example for EMT during
TABLE 1 (Continued)
Melanoma implication Factor (function) Detailed function in melanoma References NCSC function References
overexpression induces a
reversible phenotype switch in
vitro and increased metastatic





Depletion in a NRASQ61K Ink4a-








FOXD3 upregulates ERBB3, leading









NGFR+ AXL+ melanoma patient cells
represent a dormant, MAPKi-
resistant cell population. Long-
term (3 weeks) BRAFi treatment
leads to emergence of a drug-
tolerant or drug-resistant NC-like
cell state in vitro.
60,61
RXRG (nuclear receptor) Minimal residual disease in a BRAFi/
MEKi-tolerant PDX model
represents as dedifferentiated
melanoma (NGFR+ RXRG+ AQP1+
GFRA+).
28 Expressed in migrating
cranial chick NC cells.
62
Immune Evasion CD271 (receptor tyrosine
kinase)
TNFα induces dedifferentiation of
melanoma cells (NGFRhigh) and
resistance to adaptive T-cell
therapy in a murine model of
adoptive cell transfer therapy.
Long-term exposure of patient-
derived melanoma cells to
antigen-specific cytotoxic T cells
leads to enrichment of NGFRhigh
cells, which are refractory to T




Intratumoral TNFα and T-cell
accumulation induce Ezh2 in
melanoma cells originating from
NRASQ61K Ink4a-loss or B16 F10
murine models, leading to loss of
immunogenicity.
63
Abbreviations: MEK, mitogen-activated extracellular signal-regulated kinase; NC, neural crest; NCSC, neural crest stem cell; SOX10, SRY-related HMG-box
10; TF, transcription factor; YY1, Ying Yang 1. Transgenic animal models: NRASQ61K Ink4a-deficient mouse model, Tyr:NrasQ61K Cdkn2a-/-; BRAFV600E p53-
deficient zebrafish, mitfa:BRAFV600E p53-/-.
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embryonic development.4,5,87 Intriguingly, regulatory genes responsi-
ble for developmental NC EMT are reexpressed in adult malignant
melanoma,19,88 including members of the Snail, Zeb, and Twist fami-
lies49 (Table 1). Caramel et al49 showed that upon NRAS/BRAF activa-
tion in melanocytes, the EMT TFs TWIST1 and ZEB1 were
upregulated and induced dedifferentiation and neoplastic transforma-
tion. They also showed that this EMT-TF signature, when found in
late-stage melanoma patients, correlated with poor prognosis. Simi-
larly, transforming growth factor beta also acts as a potent inducer of
melanoma phenotype switching,84,89 while playing a crucial physiolog-
ical role in NC development by providing signaling cues for migration
and differentiation into several lineages.90-92
Apart from an invasive and migratory potential, epithelial cancer
cells undergoing EMT have been associated with the acquisition of
stem cell-like features.93,94 Similarly, melanoma phenotype switching
has been associated with the reemergence of signatures similar to
NCSC regulatory networks47 (Table 1). Expression of the NCSC-
associated factors CD271 and SOX1039,40 in human melanoma corre-
lates with high metastatic potential and worse patient prognosis35
(Table 1). Furthermore, Msh homeobox 1 (MSX1), which specifies the
NC at the neural border of zebrafish and xenopus,48 when
upregulated in melanoma, leads to dedifferentiation of melanoma
cells, which upregulate NCSC-associated factors such as CD271 and
induce a phenotype switch toward increased cell migration47
(Table 1). Vice versa, silencing of MSX1 reduces liver metastasis of tail
vein-injected human melanoma cells in mice.47 Also the zebrafish and
murine NC specifier FOXD3 together with PAX3, which is expressed
at the neural plate border,56,57 have been shown to induce human
melanoma invasiveness by directly regulating CXCR4,53 which in turn
regulates melanoma metastasis formation54,55 (Table 1). Finally, even
though a zebrafish study suggested otherwise,95 ectopic over-
expression of CD271 induces a phenotype switch in human mela-
noma cells, ultimately leading to an increased metastatic potential of
human melanoma cells grafted into immunocompromised mice26
(Table 1). These findings revealed a functional involvement of single
factors reminiscent of NCSCs in melanoma disease progression.
Whether, in general, the reemergence of a broader NCSC signature is
functionally implicated in melanoma metastasis formation remains to
be elucidated.
4 | DEDIFFERENTIATED MELANOMA
CELLS DISPLAY RESISTANCE TO DIFFERENT
THERAPIES
While traditionally the most common therapy for melanoma has been
surgical removal of primary tumors plus radiation and
chemotherapy,96 the advent of immune and targeted therapies signifi-
cantly improved the survival rate, especially of patients with meta-
static melanoma.33 Targeted therapies for melanoma are mostly
directed against the serine/threonine kinase BRAF or the mitogen-
activated extracellular signal-regulated kinase (MEK), leading to inhibi-
tion of the mitogen-activated protein kinase (MAPK) pathway, an
oncogenic pathway mutated and constitutively active in most melano-
mas.97,98 Immunotherapies on the other hand aim at boosting the
antitumoral activity of cytotoxic T lymphocytes (CTLs) to combat mel-
anoma.29 However, one of the major remaining challenges is the
acquisition or preexistence of melanoma cells resistant to such
therapies,99-103 which ultimately lead to relapse.
Resistance to different melanoma therapies has been associated
with cells undergoing phenotype switching and lacking pigmentation-
related differentiation genes while expressing genes reminiscent of
NC development.28-30,32,104,105 Specifically, MAPK pathway inhibition
was shown to promote the de novo generation or expansion of sub-
populations of melanoma cells expressing NCSC-associated factors
like CD27128,106 or the NC specifier gene FOXD3.58 In addition,
targeted therapy led to increased expression of genes linked to inva-
siveness like the receptor tyrosine kinase AXL106,107 (Table 1). NCSC-
like melanoma cell subpopulations were further reported to contribute
to minimal residual disease and, ultimately, to disease relapse.28,108
Conversely, another study showed that melanoma cells expressing
the melanocyte differentiation gene Dopachrome tautomerase (DCT,
also TYRP2) were intrinsically resistant to BRAF inhibition.109 How-
ever, increasing evidence supports the hypothesis that it is particularly
the dedifferentiated melanoma cell population, expressing genes remi-
niscent of NCSCs, that can resist different treatments, including
immunotherapies.
Along that line, a recent study showed that long-term exposure
of patient-derived melanoma cells to antigen-specific (MART1) T
cells led to an enrichment of CD271high melanoma cells, which
showed increased resistance to cytotoxic T cells (which recognized
differentiation and non-differentiation antigens), as well as to
BRAF and MEK inhibitors31 (Table 1). In line with these findings,
another study revealed that in a mouse adoptive T cell therapy
model, tumor necrosis factor alpha (TNFα)-induced inflammation
led to dedifferentiation of patient-derived transplanted melanoma
by upregulation of CD271 and downregulation of melanocyte-
specific antigens, which resulted in reduced tumor recognition by
infiltrating T cells32 (Table 1). Furthermore, while Boshuizen et al31
interfered with CD271 upregulation to combat T cell resistance
and relapse in their preclinical model via an unspecific heat shock
protein inhibitor, another study developed a CD271-specific
monoclonal humanized antibody to counteract CD271 function.110
The authors showed that treatment of CD271-positive human mel-
anoma grafts in NOD/scid mice with this CD271 antibody in com-
bination with natural killer or peripheral blood mononuclear
effector cells achieved a significant antitumor effect.110 Whether
such a CD271-specific antibody could combat therapy resistance
of melanoma tumors toward targeted or immune therapy remains
to be answered, but previous findings appear to support such an
approach.28,31,32
Immunotherapy-induced T-cell accumulation and TNFα have also
been shown to induce other factors reminiscent of NC development
in melanoma, such as the histone methyltransferase Ezh2, which regu-
lates mesenchymal fates during murine NC development.43 Ezh2
upregulation in melanoma led to reduced immunogenicity of B16 F10
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or NrasQ61K-mutant Ink4a-deficient murine tumors autologously
grafted onto C57BL/6 mice, while pharmacological inhibition of Ezh2
attenuated this effect and synergized with anti-CTLA-4 and IL-2
immunotherapies in mice63 (Table 1).
5 | TARGETING THE REEMERGENCE OF
NCSC-LIKE MELANOMA STATES
In line with NCSC-like cell states observed in melanoma during dis-
ease progression and treatment, increasing evidence supports
approaches targeting melanoma cells that have hijacked developmen-
tal programs. Indeed, several preclinical studies have succeeded in
targeting or inhibiting the emergence of dedifferentiated melanoma
cells to combat therapy resistance (Figure 2).
For instance, inhibiting CD271 in melanoma cells restored their
susceptibility to BRAF inhibitors.27 Likewise, suppressing the emer-
gence of dedifferentiated, NCSC-like melanoma cells upon MEK and
BRAF inhibition (MEKi and BRAFi) interfered with resistance forma-
tion in vivo.28 Specifically, this elegant study showed that a set of
NCSCs genes, such as the Retinoid X receptor gamma (RXRG), which
is expressed in chicken NCSCs,62 was induced by MEKi and BRAFi
treatment, and that pharmacological inhibition of RXRG prevented
disease relapse of patient-derived melanoma in immunocompromised
mice28 (Figure 2). Yet another study used a cytotoxic antibody
approach to target AXLhigh melanoma cells resistant to MEKi and
BRAFi, which led to reduced tumor growth and restored drug suscep-
tibility107 (Figure 2). Of note, AXL has not been identified as a regula-
tor of the embryonic NC as such, however its expression has been
associated with NCSC-reminiscent factors such as CD271.60
F IGURE 2 Interfering with dedifferentiated, neural crest stem cell (NCSC)-like melanoma cells to combat drug resistance. Different preclinical
studies successfully managed to circumvent therapy resistance of melanoma cells or patient-derived grafts in mice by targeting the reemergence
of NCSC-like melanoma states. Rambow et al28 were able to attenuate the accumulation of NCSC-like cells after BRAF/MEK inhibition by
treating patient-derived melanoma with an antagonist toward RXRG, a NCSC-associated gene strongly upregulated within their drug resistant
melanoma subpopulation. Similarly, Boshuizen et al107 successfully targeted tumor growth by combining MAPK inhibition with a cytotoxic
antibody against AXLhigh cells emerging as resistant cells after BRAF/MEK inhibition. AXL is associated with invasiveness and drug resistance in
melanoma60 but has also been associated with reemergence of NCSC states in melanoma.106 Also, Tsoi et al106 could show that MAPK inhibition
as well as pro-inflammatory signaling from immunotherapies promoted drug resistant, dedifferentiated melanoma cells, which were characterized
by increased sensitivity to ferroptosis. The authors subsequently co-treated melanoma cells with targeted therapy and the ferroptosis-inducing
drug Erastin, which led to decreased melanoma cell survival. Sáez-Ayala et al111 achieved to circumvent drug resistance by forced differentiation
of melanoma cells due to treatment with methotrexate (MTX), which induced the expression of the melanocyte differentiation marker MITF and
inhibited invasiveness. This drug was further combined with the cytotoxic prodrug TMECG, activated by tyrosinase (a target of MITF), which is
expressed in differentiated melanocytes
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Specifically the receptor tyrosine kinases AXL and CD271 (together
with EGFR and others) have been identified as marker genes for BRAF
inhibitor resistance of human melanoma cells in vitro,30 suggesting
that targeting AXLhigh drug resistant melanoma cells putatively affects
cells with NCSC-reminiscent features.
Furthermore, targeted as well as immunotherapy have been
shown to induce drug resistance, along with acquisition of NCSC-like
gene expression programs, that lead to an increased sensitivity to
ferroptosis,106 a type of programmed cell death.112 The study authors
subsequently managed to inhibit melanoma dedifferentiation and
therapy resistance by addition of ferroptosis-inducing drugs106
(Figure 2).
The opposite approach of pushing melanoma into a fully differen-
tiated cell fate to circumvent resistance formation, has been achieved
in vitro through application of methotrexate (MTX), which activates
the expresison of microphthalmia-induced TF (MITF), a key regulator
of differentiated melanocytes113 . MTX treatment further increased
melanoma cell susceptibility to a cytotoxic prodrug (TMECG), acti-
vated by tyrosinase, a target of MITF and expressed by fully differen-
tiated melanocytes111 (Figure 2).
All in all, these studies have demonstrated that interference with
melanoma dedifferentiation or, vice versa, the promotion of a fully dif-
ferentiated melanoma state can yield increased drug susceptibility and
prevention of disease relapse in preclinical models, which make this a
highly promising approach for patient therapy.
6 | CONCLUDING REMARKS
Several approaches to target the reemergence of NCSC-like cell states
in treatment-resistant melanomas (Figure 2) have shown great prom-
ise in preclinical settings. However, further in-depth studies and
proper characterization of such NCSC-like melanoma cell states are
needed to unravel the exact nature of gene regulatory networks that
lead to the most therapy-resilient, and hence aggressive, tumors.
Unfortunately, inter-patient and intratumoral heterogeneity has
always posed a substantial challenge in melanoma treatment and also
complicates the identification of exact NCSC-like programs emerging
within melanoma patients.
Currently, most studies performed on NCSC-like cells in mela-
noma and cited within this review are preclinical studies114 per-
formed on human material in vitro30,106 or in murine models,
where NC-reminiscent factors were shown to be crucial for tumor
formation and disease progression in genetically engineered mela-
noma models24,25,63 as well as in patient-derived xenograft
models.22,26,28,47 However, extensive analyses of patient materials,
which are important to support the clinical relevance of the above
discussed findings, are often missing due to limited access to sam-
ples reflecting specific stages of melanoma progression. Also, some
of the first in-depth single-cell analyses of patient tissues have
been single case reports28 rather than studies involving big patient
cohorts. Therefore, the possibility remains that the reemergence of
aggressive, therapy-resistant NCSC-like cell states observed in
preclinical models does not or not always occur during disease pro-
gression in human melanoma patients and that metastatic disease
and therapy resistance could still be established by alternative
pathways.
Another remaining question concerns whether the mutational
landscape predisposes melanoma subtypes toward the potential for
dynamic remodeling into NCSC-like cell states. For now, it is unclear
whether some of the most frequent melanoma mutations, namely,
BRAFV600E and NRASQ61K, preferably favor the reemergence of NCSC-
like cell states. Work by Zon and colleagues has shown that in
zebrafish, BRAFV600E-mutated melanomas activate a NCSC progenitor
program essential for melanoma initiation,23 while in NRASQ61K-
mutated melanomas, such a NCSC signature did not emerge at early
stages of disease but only after transformation into malignant mela-
noma.115 Whether this discrepancy is reflective of the human disease
physiology remains unclear, since tumor initiation and onset of inva-
sion and metastatic spread cannot be properly monitored or modeled
in humans. Furthermore, most preclinical studies that have associated
NCSC-like melanoma subpopulations with resistance to therapy have
addressed BRAF inhibitor resistance and accordingly used mostly
BRAF-mutated melanoma material,28,31 leading to a bias toward BRAF-
vs NRAS-mutated material under investigation.
In conclusion, future studies including human material from big-
ger, more representative patient cohorts and collected at different
time points of disease progression, specifically also during response to
therapies, are needed to address the relevance of NCSC-like mela-
noma cell states in humans. Hopefully, further single-cell studies will
allow us to answer whether NCSC-reminiscent melanoma subpopula-
tions indeed emerge in patients and whether they substantially inter-
fere with melanoma treatment. This could open promising new
avenues for designing novel therapies.
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